Cause of mortality by DLCOcSB > 60% or ≤60% of predicted in patients undergoing auto-HSCT conditioned with high-dose melphalan
| . | DLCOcSB > 60% of predicted . | DLCOcSB ≤ 60% of predicted . |
|---|---|---|
| Patients, n | 246 | 31 |
| Alive | 172 (70) | 17 (55) |
| Relapse | 66 (27) | 12 (39) |
| NRM | 4 (1) | 1 (3) |
| Cause of death (months after auto-HSCT) | Pancreatic cancer (99.5) | Pneumonia, hypoxia (12) |
| Arrhythmia (4.5) | ||
| Bronchial carcinoma (12.4) | ||
| Acute GvHD (9.8) | ||
| Unknown cause of death | 5 (2) | 1 (3) |
| . | DLCOcSB > 60% of predicted . | DLCOcSB ≤ 60% of predicted . |
|---|---|---|
| Patients, n | 246 | 31 |
| Alive | 172 (70) | 17 (55) |
| Relapse | 66 (27) | 12 (39) |
| NRM | 4 (1) | 1 (3) |
| Cause of death (months after auto-HSCT) | Pancreatic cancer (99.5) | Pneumonia, hypoxia (12) |
| Arrhythmia (4.5) | ||
| Bronchial carcinoma (12.4) | ||
| Acute GvHD (9.8) | ||
| Unknown cause of death | 5 (2) | 1 (3) |
Unless otherwise noted, data are n (%). DLCOcSB values were not available for 18 patients (6.1%) before auto-HSCT and prior to conditioning with high-dose melphalan.
GvHD, graft-versus-host disease.